

Ganesh Raghu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1200152/ganesh-raghu-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

204
papers

32,835
citations

73
h-index

181
g-index

239
ext. papers

41,232
ext. citations

12.6
avg, IF

7.02
L-index

#	Paper	IF	Citations
204	Soluble ECM promotes organotypic formation in lung alveolar model.. <i>Biomaterials</i> , 2022 , 283, 121464	15.6	0
203	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022 , 205, e18-e47	10.2	38
202	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.. <i>Annals of the American Thoracic Society</i> , 2022 , 19, 833-844	4.7	2
201	Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.. <i>Annals of the American Thoracic Society</i> , 2022 ,	4.7	1
200	Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. <i>European Respiratory Review</i> , 2021 , 30,	9.8	5
199	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	5
198	In Reply. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 1326-1327	5	
197	Reply to Morb̄-Mendoza and Khalil: Are Ground-Glass Opacities on Chest High-Resolution Computed Tomography a Manifestation of Airway Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 781-782	10.2	
196	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1839-1848	4.7	1
195	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1841-1851	27.4	12
194	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. <i>Journal of Inflammation</i> , 2021 , 18, 17	6.7	3
193	R-Scale for Pulmonary Fibrosis (PF): a simple, visual tool for the assessment of health-related quality of life. <i>European Respiratory Journal</i> , 2021 ,	13.6	2
192	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. <i>European Respiratory Review</i> , 2021 , 30,	9.8	16
191	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2021 ,	4.7	2
190	Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline: Summary for Clinicians. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 559-566	4.7	3
189	Questionnaires or Serum Immunoglobulin G Testing in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 130-147	4.7	5
188	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 211-220	10.2	20

187	The DIAMORFOSIS (DIAGnosis and Management Of lung cancerR and FibrOSIS) survey: international survey and call for consensus. <i>ERJ Open Research</i> , 2021 , 7,	3.5	5
186	Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1306-1313	10.2	12
185	Associations of β Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. <i>American Journal of Epidemiology</i> , 2021 , 190, 95-108	3.8	8
184	Transbronchial Biopsy and Cryobiopsy in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 148-161	4.7	5
183	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 96-106	35.1	38
182	Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry. <i>Lung India</i> , 2021 , 38, 5-11	1.1	0
181	Hypersensitivity Pneumonitis and (Idiopathic) Pulmonary Fibrosis Due to Feather Duvets and Pillows. <i>Archivos De Bronconeumologia</i> , 2021 , 57, 87-93	0.7	5
180	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, e3-e23	10.2	1
179	Lung transplantation for interstitial lung disease. <i>European Respiratory Review</i> , 2021 , 30,	9.8	4
178	Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. <i>European Respiratory Review</i> , 2021 , 30,	9.8	4
177	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. <i>Current Neuropharmacology</i> , 2021 , 19, 1202-1224	7.6	6
176	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	1
175	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. <i>Chest</i> , 2020 , 157, 1391-1392	5.3	0
174	Telemedicine - maintaining quality during times of transition. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 45	51.1	27
173	Reference values for high attenuation areas on chest CT in a healthy, never-smoker, multi-ethnic sample: The MESA study. <i>Respirology</i> , 2020 , 25, 855-862	3.6	6
172	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>New England Journal of Medicine</i> , 2020 , 382, 779-780	59.2	5
171	A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. <i>Chest</i> , 2020 , 158, 637-645	5.3	20
170	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 3	3.5	29

169	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. <i>Chest</i> , 2020 , 157, 1506-1512	5.3	18
168	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	
167	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). <i>Lung India</i> , 2020 , 37, 359-378	1.1	1
166	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). <i>Lung India</i> , 2020 , 37, 359	1.1	3
165	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>Chest</i> , 2020 , 157, 580-589	5.3	9
164	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , 2020 , 29,	9.8	50
163	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1620-1628	4.7	8
162	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. <i>ERJ Open Research</i> , 2020 , 6,	3.5	7
161	Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1455-1467	4.7	17
160	Methodologies of COLDICE and Cryo-PID studies: details make the difference. <i>Annals of Translational Medicine</i> , 2020 , 8, 781	3.2	0
159	Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, e36-e69	10.2	175
158	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. <i>ERJ Open Research</i> , 2020 , 6,	3.5	3
157	COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 839-842	35.1	53
156	Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to Antisynthetase Syndrome. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 901-904	4.7	3
155	Fibrotic interstitial lung diseases and air pollution: a systematic literature review. <i>European Respiratory Review</i> , 2020 , 29,	9.8	14
154	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 25-33	35.1	81
153	Risk factors for disease progression in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2020 , 75, 78-80	7.3	10
152	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 171-181	35.1	131

151	Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 926-929	35.1	3
150	Hypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 301-308	10.2	41
149	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 2518-2528	59.2	532
148	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 1183-1184	10.2	10
147	Sarcoidosis and idiopathic pulmonary fibrosis: The same tale or a tale of two diseases in one. <i>Respiratory Medicine</i> , 2019 , 160, 105668	4.6	0
146	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 487-496	35.1	61
145	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	7
144	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 657-664	35.1	42
143	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1146-1153	10.2	33
142	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019 , 9, 14802	4.9	10
141	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000443	5.6	11
140	Hypersensitivity pneumonitis: Clinical manifestations - Prospective data from the interstitial lung disease-India registry. <i>Lung India</i> , 2019 , 36, 476-482	1.1	2
139	Idiopathic Pulmonary Fibrosis Guideline Recommendations. Need for Adherence to Institute of Medicine Methodology?. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 681-686	4.7	10
138	Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. <i>European Respiratory Review</i> , 2019 , 28,	9.8	56
137	Accuracy of Digital Tomosynthesis of the Chest in Detection of Interstitial Lung Disease Comparison With Digital Chest Radiography. <i>Journal of Computer Assisted Tomography</i> , 2019 , 43, 109-114	2.2	2
136	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 336-347	10.2	41
135	Reply to Moodley and to Ravaglia et al. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 667-669	10.2	
134	Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 368, 169-178	4.7	13

133	Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2019 , 146, 42-48	4.6	20
132	Hypersensitivity pneumonitis and its correlation with ambient air pollution in urban India. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	14
131	Diagnosis of idiopathic pulmonary fibrosis by virtual means using "IPFdatabase"- a new software. <i>Respiratory Medicine</i> , 2019 , 147, 31-36	4.6	3
130	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	10
129	Response to Letter to Editor regarding "Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?". <i>Respiratory Medicine</i> , 2019 , 149, 43-44	4.6	
128	Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	12
127	2018 Clinical Practice Guideline Summary for Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 285-290	4.7	12
126	Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	1
125	Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 978-982	3.8	12
124	Lung transplantation in idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 375-385	3.8	26
123	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 154-160	35.1	76
122	Identification of usual interstitial pneumonia pattern using RNA-Seq and machine learning: challenges and solutions. <i>BMC Genomics</i> , 2018 , 19, 101	4.5	15
121	Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	30
120	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 707-714	35.1	74
119	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. <i>Respiratory Medicine</i> , 2018 , 140, 108-114	4.6	8
118	Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis 2018 , 195-204		
117	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018 , 153, 94-104	5.3	47
116	Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. <i>Chest</i> , 2018 , 154, 1359-1370	5.3	25

115	Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy. <i>Respiratory Medicine</i> , 2018 , 144S, S13-S19	4.6	13
114	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). <i>European Respiratory Journal</i> , 2018 , 52,	13.6	41
113	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2018 , 379, 1722-1731	59.2	135
112	Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?. <i>Respiratory Medicine</i> , 2018 , 144S, S20-S27	4.6	21
111	Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS [®] trials. <i>Respiratory Research</i> , 2018 , 19, 167	7.3	27
110	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, e44-e68	10.2	1426
109	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	20
108	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2299-2307	27.4	107
107	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 78-85	10.2	108
106	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	29
105	Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	11
104	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. <i>Thorax</i> , 2017 , 72, 472-474	4.6	15
103	Reply: "The ILD-India Registry: Ignoratio Elenchi" and "The ILD-India Registry: Look Before You Leap". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 837-839	10.2	4
102	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1249-1254	10.2	105
101	Pleuroparenchymal fibroelastosis associated with telomerase reverse transcriptase mutations. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	5
100	High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1434-1442	10.2	41
99	Antacid use and subclinical interstitial lung disease: the MESA study. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	1
98	Current approaches to the management of idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2017 , 129, 24-30	4.6	37

97	Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 680-689	10.2	238
96	Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. <i>Chest</i> , 2017 , 152, 103-112	5.3	35
95	Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. <i>International Journal of Cardiology</i> , 2017 , 241, 457-462	3.2	24
94	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 61-71	35.1	52
93	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 22-32	35.1	142
92	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e1-e2	35.1	12
91	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	61
90	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. <i>European Respiratory Review</i> , 2017 , 26,	9.8	22
89	Idiopathic pulmonary fibrosis. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17074	51.1	395
88	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	50
87	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1031-1039	10.2	28
86	Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	51
85	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 1646-1654	4.7	54
84	Interstitial Lung Disease in India. Results of a Prospective Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 801-813	10.2	91
83	Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. <i>European Respiratory Journal</i> , 2016 , 48, 1710-1720	13.6	164
82	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. <i>Lancet Respiratory Medicine</i> , 2016 , 4, e46-e47	35.1	5
81	Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?. <i>BMC Medicine</i> , 2016 , 14, 22	11.4	6
80	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 265-75	10.2	653

79	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. <i>Clinical Infectious Diseases</i> , 2016 , 62, 313-319	11.6	64
78	Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. <i>Chest</i> , 2016 , 149, 756-66	5.3	112
77	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. <i>BMC Medicine</i> , 2016 , 14, 18	11.4	54
76	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016 , 47, 1481-91	13.6	112
75	Treatment of Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 115-7	4.7	15
74	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. <i>Journal of Rheumatology</i> , 2016 , 43, 1672-9	4.1	163
73	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of $\geq 50\%$ of Predicted Value. <i>Lung</i> , 2016 , 194, 739-43	2.9	76
72	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. <i>Thorax</i> , 2016 , 71, 1082-1090	7.3	43
71	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. <i>European Respiratory Journal</i> , 2016 , 47, 1293-5	13.6	23
70	Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. <i>European Respiratory Journal</i> , 2016 , 48, 179-86	13.6	154
69	Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 699-711	3.8	6
68	Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 1345-52	10.2	57
67	Idiopathic pulmonary fibrosis: combating on a new turf. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 430-2	35.1	4
66	Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. <i>European Respiratory Journal</i> , 2016 , 48, 826-32	13.6	39
65	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. <i>European Respiratory Journal</i> , 2016 , 48, 1442-1452	13.6	74
64	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, e3-19	10.2	1122
63	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 388-96	35.1	57
62	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. <i>European Respiratory Journal</i> , 2015 , 46, 243-9	13.6	35

61	Rheumatoid arthritis-associated lung disease. <i>European Respiratory Review</i> , 2015 , 24, 1-16	9.8	135
60	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. <i>European Respiratory Journal</i> , 2015 , 46, 1740-50	13.6	64
59	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. <i>European Respiratory Journal</i> , 2015 , 46, 1113-30	13.6	218
58	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. <i>European Respiratory Journal</i> , 2015 , 46, 1370-7	13.6	88
57	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1475-82	10.2	187
56	Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 981-7	4.7	63
55	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. <i>Journal of Translational Medicine</i> , 2015 , 13, 249	8.5	79
54	Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. <i>Chest</i> , 2015 , 148, 1083-1092	5.3	20
53	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 473-82	35.1	81
52	Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2014 , 370, 2093-101	59.2	343
51	Smoking-related idiopathic interstitial pneumonia. <i>European Respiratory Journal</i> , 2014 , 44, 594-602	13.6	27
50	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT--authorsPreply. <i>Lancet Respiratory Medicine</i> , 2014 , 2, e5-6	35.1	1
49	Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2014 , 370, 2071-82	59.2	2337
48	Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 566-72	35.1	348
47	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 277-84	35.1	135
46	Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. <i>Chest</i> , 2014 , 146, 1256-1262	5.3	24
45	An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. <i>European Respiratory Journal</i> , 2014 , 44, 1479-503	13.6	338
44	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>European Respiratory Journal</i> , 2014 , 44, 1296-307	13.6	126

43	Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 685-94	35.1	214
42	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 733-48	10.2	2176
41	Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. <i>European Respiratory Journal</i> , 2013 , 42, 1622-32	13.6	166
40	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 369-76	35.1	276
39	Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. <i>Annals of Internal Medicine</i> , 2013 , 158, 641-9	8	327
38	An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1004-14	10.2	593
37	Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. <i>Lancet</i> , 2012 , 380, 699-701	40	12
36	Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1044-8	10.2	165
35	Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2012 , 366, 1968-77	59.2	992
34	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 788-824	10.2	4665
33	Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2011 , 365, 1079-87	59.2	728
32	Rheumatoid arthritis-interstitial lung disease-associated mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 372-8	10.2	289
31	Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 459-66	10.2	294
30	Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. <i>Chest</i> , 2011 , 139, 441-443	5.3	57
29	BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 92-9	10.2	333
28	The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. <i>Respiratory Medicine</i> , 2010 , 104, 296-304	4.6	167
27	Does chronic microaspiration cause idiopathic pulmonary fibrosis?. <i>American Journal of Medicine</i> , 2010 , 123, 304-11	2.4	156
26	Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. <i>Chest</i> , 2009 , 136, 16-22	5.3	33

25	BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 75-81	10.2	407
24	Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 948-55	10.2	269
23	Telomere shortening in familial and sporadic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 729-37	10.2	379
22	Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 1054-60	10.2	190
21	Acute exacerbations of idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 636-43	10.2	823
20	Incidence and prevalence of idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 810-6	10.2	916
19	Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. <i>Chest</i> , 2006 , 129, 794-800	5.3	177
18	The clinical course of patients with idiopathic pulmonary fibrosis. <i>Annals of Internal Medicine</i> , 2005 , 142, 963-7	8	423
17	High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 488-93	10.2	373
16	Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. <i>Chest</i> , 2005 , 127, 171-7	5.3	181
15	Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 904-10	10.2	450
14	A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2004 , 350, 125-33	59.2	545
13	Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. <i>Clinics in Chest Medicine</i> , 2004 , 25, 409-19, v	5.3	48
12	Idiopathic pulmonary fibrosis: current trends in management. <i>Clinics in Chest Medicine</i> , 2004 , 25, 621-36, v	5.3	23
11	The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. <i>American Journal of Medicine</i> , 2003 , 115 Suppl 3A, 60S-64S	2.4	50
10	Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 1061-9	10.2	378
9	Assessment of health-related quality of life in patients with interstitial lung disease. <i>Chest</i> , 1999 , 116, 1175-82	5.3	210
8	The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. <i>Chest</i> , 1999 , 116, 1168-74	5.3	322

7	Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 158, 1804-8	10.2	430
6	Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 158, 424-30	10.2	104
5	Interstitial Lung Disease: A Diagnostic Approach: Are CT Scan and Lung Biopsy Indicated in Every Patient?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995 , 151, 909-914	10.2	101
4	Human lung fibroblast subpopulations with different C1q binding and functional properties. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992 , 6, 382-9	5.7	21
3	Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. <i>Cancer</i> , 1991 , 67, 2407-9	6.4	25
2	Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. <i>The American Review of Respiratory Disease</i> , 1991 , 144, 291-6		326
1	Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. <i>The American Review of Respiratory Disease</i> , 1988 , 138, 703-8		130